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C rohn’s disease (CD) is a chronic and progressive disease characterized by periods of remission and 
clinical relapses.  CD patients often require bowel resec-
tion and urgent hospitalization due to unexpected com-
plications such as stenosis or abscess,  which greatly 
reduce their quality of life.  In clinical practice,  many 
CD patients experience disabling courses despite the 
provision of specific treatments; in contrast,  10-25% of 
the patients enjoy a favorable disease course without 
any complications [1-3].  Before the era of biologics,  
although corticosteroid therapy was practically the only 
effective treatment option for moderate to severe CD,  
28-57% of patients with newly developed CD did not 
require corticosteroids throughout their lives [4].  Thus,  
the disease courses of CD can vary widely among 
patients.
The first anti-tumor necrosis factor (TNF) agent was 
approved by the U.S.  Food and Drug Administration in 
1998,  and anti-TNF agents have since become a main-
stay treatment for CD.  Although a number of research-
ers and clinicians consider so-called “top-down ther-
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Determining factors that predict a favorable disease course without anti-tumor necrosis factor (TNF) agents 
would help establish a more cost-effective strategy for Crohn’s disease (CD).  A retrospective chart review was 
performed for CD patients with disease durations > 10 years who had not received anti-TNF agents as first-line 
therapy.  Patients were divided into 2 groups: those who received neither anti-TNF agents nor bowel resection 
(G1),  and those who had received an anti-TNF agent and/or bowel resection (G2).  The patient backgrounds,  
therapies and clinical courses were compared between the groups.  A total of 62 CD patients met the inclusion 
criteria (males: 71%; median duration of follow-up: 19 years).  Six patients were included in G1; they were 
significantly less likely to have upper gastrointestinal lesions than G2 (p= 0.007).  A multivariate analysis 
revealed that the significant factors for avoidance of bowel resection without anti-TNF treatment were 
non-stricturing and non-penetrating behaviors,  and absence of upper gastrointestinal lesions at the diagnosis 
(hazard ratios 0.41 and 0.52; p= 0.004 and 0.04,  respectively).  In consideration of the long treatment course of 
CD,  patients with non-stricturing and non-penetrating behaviors and no upper gastrointestinal lesions should 
not be treated with anti-TNF agents as first-line therapy.
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apy” to be the best strategy for treating CD patients,  
many physicians have found that CD patients do not 
always require anti-TNF agent treatment at the time of 
the diagnosis or during their long disease course.  
Additionally,  because anti-TNF agents are more expen-
sive than oral corticosteroids or immunomodulators,  
the indiscreet use of these agents results in a substantial 
economic burden for both patients and the medical 
community.  Given the recent increase in the numbers 
of CD patients globally and the development of new 
“high-cost” biologics,  it is important to differentiate 
high-risk CD patients who will need aggressive treat-
ment with biologics from CD patients who can tolerate 
the step-up strategy without needing biologics.
Although several studies have identified factors that 
affect the disease course in CD patients [5-7],  the 
requirement of anti-TNF agents has not been counted as 
a risk factor or a consequence of severe or disabling dis-
ease courses.  Therefore,  to identify CD patients who 
absolutely do not require an anti-TNF agent,  we inves-
tigated factors predicting a favorable disease course 
without anti-TNF treatment in CD patients with a dis-
ease duration exceeding 10 years.
Methods
Patients. We performed a retrospective chart 
review for all CD patients with disease onset from 
January 1983 to December 2006 who had been followed 
at Okayama University Hospital until May 2016.  
Patients who were not given a full examination (includ-
ing esophagogastroduodenoscopy [EGD]) for intestinal 
lesions were excluded.
None of the patients had received an anti-TNF agent 
as the first-line therapy because infliximab,  the first 
anti-TNF agent approved in Japan,  only became avail-
able at our institute in 2007.  We divided the patients 
into 2 groups: those who were not treated with an anti-
TNF agent and did not undergo bowel resection (G1),  
and those who were treated with an anti-TNF agent 
and/or underwent bowel resection (G2) during their 
disease course until the last follow-up.  The patients’ 
backgrounds,  clinical manifestations,  therapies,  and 
disease courses during the long-term follow-up were 
investigated and compared.  We sought to identify any 
factors that could be used to predict a favorable disease 
course,  i.e.,  disease courses with no bowel resection 
and without the use of anti-TNF agents.  We defined the 
length of favorable disease courses as 2 different peri-
ods: 10 years and 5 years (Fig. 1A , B).
This retrospective analysis was approved by the 
institutional review board of Okayama University 
Graduate School of Medicine,  Dentistry,  and 
Pharmaceutical Sciences (No. 1506-046).  There were no 
conflicts of interest or sponsors of this study.
Diagnosis and classification of CD. The diagno-
sis of CD was based on a combination of conventional 
criteria that included clinical symptoms and the find-
ings obtained by endoscopy,  histopathology,  and/or 
radiography.  We have routinely given patients diag-
nosed with CD several examinations before starting 
their treatment: a blood examination,  EGD,  total 
colonoscopy including observation of the terminal 
ileum,  abdominal computed tomography,  and small-
bowel follow-through.  The disease locations and dis-
ease behavior were classified according to the Montreal 
classification [8].  In addition,  the presence/absence of 
upper gastrointestinal (GI) lesions was determined 
according to the EGD findings.  Upper GI lesions 
included both ulcers and erosions in the antrum and 
erosions and notched signs in the duodenum [9-12].  A 
bamboo joint-like appearance (BLA) was also regarded 
as a characteristic upper GI finding of CD [13].  A BLA 
is characterized by longitudinal folds with traversing 
erosive fissures or linear furrows,  often found in the 
lesser curvature of the gastric body and cardia,  and 
sometimes observed in the bulb of the duodenum 
[14 , 15] (Fig. 2).
Treatment policy for CD including the administra-
tion of anti-TNF agents. All CD patients were 
treated with the step-up policy,  based on the guidelines 
published by the British Society of Gastroenterology,  
the European Crohn’s and Colitis Organization,  and the 
American College of Gastroenterology [1-3].  In gen-
eral,  if tolerated,  a sufficient dose of 5-aminosalicylate 
(ASA) and an elemental diet were administered to 
patients with mild to moderate activity.  CD patients 
with severe activity or those refractory to 5-ASA or an 
elemental diet were considered to be indicated for cor-
ticosteroid.  In the patients with steroid-refractory or 
steroid-dependent courses,  an immunomodulator was 
started.
None of the patients were administered anti-TNF 
agents before December 2006,  even when they under-
went intestinal resections or experienced repeated flare-
ups.  We started to use the anti-TNF agents for remis-
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(A) Over 10 year-favorable clinical courses (B) Over 5 year-favorable clinical courses
Fig. 1　 Patient flow chart.  A,  Over 10 year-favorable clinical courses; B,  Over 5 year-favorable clinical courses.
(A)
(B)
Fig. 2　 Gastroduodenal endoscopic findings of the 
CD patients.  Representative images of (A) the bam-
boo joint-like appearance (BLA) in the cardia of the 
stomach and (B) erosions and notched signs 
(arrows) in the duodenum.  The lesions were high-
lighted by spraying with indigo carmine dye.
sion induction and maintenance therapy if appropriate,  
only after the Ministry of Health,  Labor and Welfare in 
Japan approved infliximab as maintenance therapy for 
CD in January 2007.  At our institute,  the indications 
for the administration of anti-TNF agents were as fol-
lows: (1) failure to respond to standard treatments,  
including elemental diet,  5-ASA,  corticosteroids and 
immunomodulators; and (2) a moderate to severe 
symptoms score > 150 on the Crohn’s Disease Activity 
Index (CDAI) despite existing treatments and being at 
high risk for intestinal failure (i.e.,  having a < 2 m length 
of residual small intestine after bowel resection and/or 
polysurgery).
Statistical analyses. The patient characteristics 
were compared using the chi-squared test,  Fisher’s 
exact test,  and the Mann-Whitney U-test.  Univariate 
and multivariate analyses using a Cox proportional haz-
ards regression model were conducted to identify vari-
ables associated with avoiding both the use of anti-TNF 
agents and bowel resection.  Variables with p-values 
< 0.10 in a univariate analysis were further tested in a 
multivariate analysis.  The hazard ratios (HRs) with 95% 
confidence intervals (CIs) were calculated.  The rates of 
using anti-TNF agents or undergoing a bowel resection 
after the CD diagnosis were analyzed by the Kaplan-
Meier method.  A statistical comparison was carried out 
by the log-rank test.  P-values < 0.05 were considered 
significant.  All of the statistical analyses were per-
formed using the JMP pro software program,  ver. 12 
(SAS Institute,  Cary,  NC,  USA).
Results
Patient characteristics. Eighty-nine patients were 
diagnosed with CD from 1983 to 2006 at Okayama 
University Hospital.  Of these,  as indicated in Fig. 1A,  
we excluded the 23 patients who were lost to follow-up 
before 10 years and the 4 patients who had not under-
gone an EGD examination at the diagnosis.  Among the 
remaining 62 patients,  all of whom had maintained 
steroid-free remission at the last visit of the study 
period,  38 patients received anti-TNF agents during 
their ≥ 10-year disease course,  and the other 24 patients 
did not.  Of the 24 patients without treatment with an 
anti-TNF agent,  18 underwent bowel resections at least 
once,  and only the remaining 6 patients had favorable 
clinical courses without bowel resection (G1).  In G1,  
only one patient had both stricturing and an upper GI 
lesion and had been in remission with an immuno-
modulator and elemental diet for 20 years.  Among the 
38 biologic users,  11 patients had never undergone 
bowel resections,  and the other 27 patients had under-
gone at least one bowel resection.  The 56 patients who 
were treated with anti-TNF agents and/or bowel resec-
tions once or more during their disease courses were 
classified as G2 according to their treatment history of 
anti-TNF agents and bowel resections.
When we redefined the length of a favorable clinical 
course as 5 years,  83 patients were included between 
1983 and 2006 (Fig. 1B).  In this redefined group,  61 
patients were biologics non-users during their 5-year 
disease course,  and 26 patients who had never under-
gone bowel resections for ≥ 5 years were included in G1.  
The remaining 57 patients comprised G2.
The clinical characteristics of the analyzed patients 
over the 10-year favorable clinical courses are summa-
rized in Table 1.  The average duration of follow-up was 
19 years.  The patients in G1 were significantly less likely 
to have upper GI lesions than those in G2 (1 [17%] vs. 
40 [67%],  p = 0.007).  None of the other factors (includ-
ing the Montreal classification and medications received 
during the follow-up) differed significantly between the 
2 groups.  In the analysis of the redefined groups over 
the 5-year favorable clinical courses,  there were no sig-
nificant differences between G1 and G2 (data not shown).
Factors associated with bowel resection and/or use 
of anti-TNF agents. We investigated the factors pre-
dicting a favorable clinical course for 10 years among 
the patients who had never undergone bowel resections 
and did not use anti-TNF agents—i.e.,  the factors for 
inclusion in G1.  The multivariate analysis revealed that 
(1) the absence of upper GI lesions and (2) non-stric-
turing and non-penetrating behavior in the Montreal 
classification were significant factors: HR 0.52,  95%CI:  
0.27-0.98 and HR 0.41,  95%CI: 0.22-0.75,  respectively 
(Table 2).  When the minimum period for a favorable 
clinical course was limited to 5 years,  non-stricturing 
and non-penetrating behavior was the only significant 
factor: HR 0.01,  95%CI: 0-0. 01 (Table 3).
Ratios of patients with neither bowel resections nor 
anti-TNF agent treatments. We performed a 
Kaplan-Meier analysis to examine the ratios of patients 
with neither bowel resections nor the use of anti-TNF 
agents in the total patient series.  The time to bowel 
resection or use of anti-TNF agents according to the 
predictive factors for a 10 year-favorable disease course 
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is shown in Figure 3.  The patients without upper GI 
lesions were less likely to undergo a bowel resection or 
be treated with anti-TNF agents compared to the 
patients with such lesions,  although a log-rank test did 
not reveal significance (Fig. 3A; p = 0. 10).  In contrast,  
the patients without stricturing and penetrating behav-
ior were significantly less likely to undergo bowel resec-
tions or be treated with anti-TNF agents (Fig. 3B;  
p = 0.04,  log-rank test).
The additional prognostic curves showed that the 
patients without stricturing and penetrating behavior 
and without upper GI lesions had the lowest risk of 
bowel resection or anti-TNF agent administration,  
whereas those with stricturing or penetrating behavior 
plus upper GI lesions were the most highly likely to 
undergo bowel resections or anti-TNF agents.  The 
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Table 2　 A multivariate analysis of predictive factors associated with a 10-year favorable disease course
Risk Factors
Univariate Multivariate
p-value HR (95% C.I.) p-value
Age ≥40 years at diagnosis 0.21
Sex (female) 0.43
Disease duration 0.45
Montreal classification
　Location (L1 / L2+L3)† 0.47
　Behavior (B1 / B2+B3)‡ 0.052 0.41 (0.22-0.75) 0.004
　Perianal disease (-) 0.059 0.51 (0.27-1.03) 0.060
Smoking habit (-) 0.14
Upper gastrointestinal lesions (-) 0.096 0.52 (0.27-0.98) 0.042
Treatment during follow-up
　Immunomodulators (-) 0.25
　Corticosteroids (-) 0.79
†L1,  ileal lesion; L2,  colonic lesion; L3,  ileocolonic lesion.
‡B1,  non-stricturing,  non-penetrating;  B2,  stricturing; B3,  penetrating.
Table 1　 Patientsʼ background characteristics in G1 and G2 groups
Total (n=62) G1 (n=6) G2 (n=56) p-value
Gender (Male) 4 (67%) 40 (71%) 0.81
Age at diagnosis (year)＊ 29 (20-38) 24 (18-30) 0.22
Follow-up periods (year)＊ 16 (12-24) 19 (14-26) 0.41
Age at diagnosis＊＊
　A1 / A2 / A3 1 (17%) /5 (83%) /0 (0%) 3 (5%) /48 (86%) /5 (9%) 0.62
Location at diagnosis†
　L1 / L2 / L3 1 (17%) /3 (50%) /2 (33%) 15 (27%) /6 (11%) /35 (63%) 0.61
Behavior at diagnosis‡
　B1 / B2 / B3 5 (83%) /1 (17%) /0 (0%) 34 (61%) /17 (30%) /5 (9%) 0.25
　Perianal disease 0 (0%) 14 (25%) 0.13
Smoking (Yes) 2 (33%) 11 (20%) 0.43
Upper gastrointestinal lesions 
Medications during follow-up 1 (17%) 40 (67%) 0.007
　Biologics 0 (0%) 38 (68%) 0.001
　Corticosteroids 1 (17%) 19 (34%) 0.39
　Immunomoduators 3 (50%) 36 (64%) 0.49
　Elemental diet 3 (50%) 29 (52%) 1.00
＊Median (IQR)
＊＊A1,  <16 years; A2,  17-40 years; A3,  >40 years.
†L1,  ileal lesion; L2,  colonic lesion; L3,  ileocolonic lesion.
‡B1,  non-stricturing,  non-penetrating; B2,  stricturing; B3,  penetrating.
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Table 3　 A multivariate analysis of the predictive factors associated with a 5-year favorable disease course
Risk factors
Univariate Multivariate
p-value HR (95% C.I.) p-value
Age ≥40 years at diagnosis 0.59
Sex (female) 0.51
Disease duration 0.22
Montreal classification
　Location (L1 / L2+L3)† 0.20
　Behavior (B1 / B2+B3)‡ 0. 03 0.01 (0-0.01) 0.025
　Perianal disease (-) 0.086 0.30 (0.82-13.5) 0.071
Smoking habit (-) 0.33
Upper gastrointestinal lesions (-) 0.38
Treatment during follow-up
　Immunomodulators (-) 0.15
　Corticosteroids (-) 0.99
†L1,  ileal lesion; L2,  colonic lesion; L3,  ileocolonic lesion.
‡B1,  non-stricturing,  non-penetrating;  B2,  stricturing;  B3,  penetrating.
(A)
Upper GI (-)
Upper GI (+)
p=0.10, log-rank test
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Fig. 3　 Kaplan-Meier curves for the patients with 10 year-favor-
able courses according to variables generated through the Cox 
model.  A,  The patients without upper GI lesions were less likely to 
undergo a bowel resection or be treated with anti-TNF agents than 
those with lesions,  although the log-rank test did not show signifi-
cance (p=0.10,  log-rank test); B,  The patients without stricturing 
and penetrating behavior were significantly less likely to undergo a 
bowel resection or be treated with anti-TNF agents (p=0.04,  log-
rank test); C,  The patients without stricturing and penetrating 
behavior and no upper GI lesions were at the lowest risk of bowel 
resection and anti-TNF agent administration,  while those with stric-
turing or penetrating behavior with upper GI lesions were the most 
likely to undergo a bowel resection or be treated with anti-TNF 
agents.  The patients with either of these factors showed an inter-
mediate risk (p=0.002,  log-rank test).
patients with either factor showed an intermediate risk 
of bowel resection or anti-TNF agent treatment 
(Fig. 3C: p = 0.002,  log-rank test).  These results suggest 
that the disease behavior and the presence of upper GI 
lesions at the diagnosis affect the prognosis of CD 
patients.
Discussion
We investigated factors that could predict a favorable 
disease course in CD patients who have not been 
treated with anti-TNF agents.  The results of our analy-
ses showed that non-stricturing and non-penetrating 
behavior and the absence of upper GI lesions at the 
diagnosis were factors associated with no bowel resec-
tion and no anti-TNF agents over both the short-term 
and long-term disease courses.  A novel finding of this 
study is that the presence of upper GI lesions including 
a BLA is a prognostic factor for CD patients during their 
long-term disease courses.
Several studies have reported factors predicting the 
disease course of CD [5 , 6 , 16-19].  However,  few 
reports have identified the factors associated with not 
using anti-TNF agents.  Although anti-TNF agents are 
potent medications for CD,  there are several draw-
backs,  including severe adverse events,  frequent losses 
of response,  and extremely high cost.  It can also be 
difficult to discontinue maintenance treatment with 
these agents due to the risk of relapse and safety con-
cerns regarding re-administration.  Although some 
investigators emphasize the importance of top-down 
therapy,  it is apparent that not all CD patients require 
treatment with anti-TNF agents.  It would thus be quite 
useful to know which factors can be used to identify CD 
patients who will not need treatment with anti-TNF 
agents.  Our findings in this report,  therefore,  appear to 
be unique and helpful in the treatment of CD in clinical 
practice.
Several research groups have used a variety of defi-
nitions for favorable or disabling disease courses in 
attempts to identify predictive factors in CD.  For exam-
ple,  Beaugerie et al.  defined a disabling course as a 
requirement of more than 2 steroid courses,  steroid 
dependence,  hospitalization for disease flare or compli-
cation,  disabling chronic symptoms for a cumulative 
time > 12 months,  and the need for immunosuppres-
sive therapy,  intestinal resection or surgery for perianal 
disease [5].  The definitions of complicated disease 
courses determined by other researchers have included 
single or multiple surgeries,  stricturing and penetrating 
behavior,  hospitalization and/or postoperative recur-
rences [6, 17-27].  In contrast,  Kruis et al.  defined mild 
CD status as receiving no therapy other than 5ASA 
throughout the follow-up,  or 5ASA in combination 
with a single short (< 12 week) course of low-dose 
(≤ 40 mg/day) corticosteroids at the start of the treat-
ment [16].
In contrast to these reports,  we defined a favorable 
disease course rather simply,  as no bowel resection and 
not using an anti-TNF agent during ≥ 10 years’ follow- 
up,  since the use/non-use of such agents in CD patients 
is a great concern in clinical practice.  Although we ini-
tially planned to include “steroid-free remission” and 
“absence of adverse effects of corticosteroids” in the 
definition of a favorable disease course,  all of the 
patients met these criteria at the time of the last follow- 
up.  Therefore,  the patients classified in G1 experienced 
disease courses with no bowel resection,  without the 
use of anti-TNF agents and without complications asso-
ciated with corticosteroids — which a majority of 
inflammatory bowel disease specialists would accept as 
a definition of a favorable disease course in CD.
Beaugerie et al.  showed that age at onset,  perianal 
lesions,  and the requirement for steroids to control the 
first flare were predictive factors of disabling disease [5].  
In our study as well,  a lack of perianal disease was 
nearly significant as a predictor for avoiding anti-TNF 
agents or bowel resection (p = 0.06).  Corticosteroid use 
was not a factor affecting the disease courses in our 
patients,  due to the extremely low rate of corticosteroid 
use in the patients with a favorable disease course.  The 
preference in Japan for an elemental diet over cortico-
steroids for patients with relatively mild CD may have 
contributed to this result.
In their retrospective study of patients followed for 
> 15 years,  Cosnes et al.  observed that younger age at 
the diagnosis,  a smoking history,  and short duration of 
disease in CD were associated with disease severity 
when they defined severe status as one of the following:  
active disease for > 3 consecutive years,  more than one 
intestinal surgery,  the establishment of a permanent 
stoma,  death related to CD,  and complications of CD 
or CD treatment [7].  Although the definition of non- 
severe status in that study differs from the favorable 
disease course definition that we used herein,  our anal-
yses indicated that the age at the diagnosis,  smoking 
habit and duration of disease were not significant fac-
tors.  These factors have been shown to be associated 
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with a poor prognosis or aggravation of the disease sta-
tus in CD in other studies [5 , 17-28],  but in real-world 
data,  these are not always detected as risk factors,  
because CD is generated by multiple factors including 
genetics,  intestinal flora,  and the patient’s living envi-
ronment,  with great heterogeneity [29 , 30].
Although the patients in G1 were defined clearly and 
the predicting factors for G1 were identified,  G2 patients 
had various disease courses and treatments,  and this 
diversity made it difficult to determine the factors pre-
dicting the CD patients’ prognosis.  In fact,  61% of G2 
was non-stricturing and non-penetrating at diagnosis,  
and 33% had not received ant-TNF agents for 10 years.  
The diversity of G2 confirms that the disease courses of 
CD patients are often heterogeneous and are deter-
mined by various factors.
Focusing on upper GI lesions in CD,  Wolters et al.  
reported that CD patients with lesions were at an 
increased risk for the first recurrence [27].  To the best 
of our knowledge,  their study referred to upper GI 
lesions as a significant predictive factor of CD for the 
first time.  Unfortunately,  however,  a clear definition of 
upper GI lesions was not provided in that study,  and it 
was not stated whether a BLA was included.  The BLA is 
a stable landmark for CD regardless of the disease activ-
ity or use of anti-TNF agents,  and the inter-observer 
agreements for a BLA are higher than those for other 
upper GI findings such as gastric lesions or duodenum 
notched signs and erosions [31 , 32].  We have previ-
ously focused on the BLA as a specific finding of CD 
and found that the incidence rate of BLA in CD patients 
was significantly higher than that in patients with ulcer-
ative colitis or gastroesophageal reflux disease (CD,  
44%; ulcerative colitis,  5%; gastroesophageal reflux 
disease,  0%) [33].  In the present study,  41 (66%) 
patients had upper GI lesions,  and 26 (42%) had a BLA.  
In particular,  17 (28%) patients had only a BLA as the 
findings in the upper GI tract,  and this prevalence is 
consistent with that of previous reports [15 , 28 , 32-37].  
Collectively,  these results indicate that the meticulous 
observation of upper GI lesions,  including a BLA 
revealed by EGD,  is relevant in the determination of 
treatment strategies for CD.
In our analysis limited to a 5-year course,  upper GI 
lesions were not a significant factor in the multivariate 
analysis of the predictive factors associated with a 
favorable disease course,  despite their significance in 
the 10-year analysis.  Although CD has a chronic pro-
gressive disease course which often makes intestinal 
lesions such as stenosis and fistulas irreversible,  it 
sometimes takes a long time to progress to intestinal 
lesions that need bowel resection or anti-TNF agents 
and not all patients require anti-TNF agents or bowel 
resections immediately after their diagnosis.  Therefore,  
we considered that the clinical importance of upper GI 
lesions became more clear with a longer follow-up 
period.
Given our results,  we propose the following clinical 
management strategy for patients with newly developed 
CD: first,  of course,  thorough examinations of the GI 
tract,  including EGD examination,  should be per-
formed.  On EGD,  a BLA should be noted as a relevant 
finding.  Patients without stricturing and penetrating 
behavior and showing the absence of upper GI lesions 
should be treated with the step-up strategy without 
immediate use of anti-TNF agents.  In contrast,  for 
patients with stricturing or penetrating behavior plus 
upper GI lesions,  prompt use of anti-TNF agents 
should be considered as a treatment option.  The treat-
ment strategy for the remaining patients (not included 
in either type) should be considered based on the 
patient’s status,  including the disease behavior and the 
patient’s desires.  For those patients,  however,  the top-
down strategy cannot be recommended,  as other safer 
and lower-cost treatments may be effective.
Our study has several limitations,  including its ret-
rospective design,  small number of patients,  and sin-
gle-center setting.  However,  it is impractical to per-
form a prospective study with an observation period 
exceeding 10 years.  In the treatment of CD,  not only 
short-term but long-term perspectives are necessary.  
We investigated factors that could be associated with a 
favorable disease course over both the short and long 
terms,  i.e.,  5 years and 10 years.  Moreover,  the condi-
tion that no CD patients receive an anti-TNF agent as 
the first-line therapy could not be enforced going for-
ward prospectively.  Nonetheless,  the results of our 
retrospective analysis,  despite its relatively small scale,  
will be valuable for the considerations of current and 
future treatment strategies for CD.
In conclusion,  our long-term follow-up study 
revealed that in CD patients not treated with an anti-
TNF agent,  the absence of stricturing and penetrating 
behavior and the absence of upper GI lesions (including 
BLA) were predictors of a favorable disease course.  
Anti-TNF agents are potently effective but are not an 
272 Inokuchi et al. Acta Med.  Okayama　Vol.  74,  No.  4
essential medication for CD.  Our findings will help 
determine more efficient and cost-effective treatment 
strategies for patients with CD.
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